A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

NCT01357161 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: adavosertib
DRUG: Placebo
DRUG: paclitaxel
DRUG: carboplatin

Sponsor

Merck Sharp & Dohme LLC